Semax 30mg Research Peptide
Semax 30mg provides a larger bulk quantity of research-grade Semax (ACTH 4-10 derived heptapeptide) for extended or multi-model neurological research protocols. Semax is a synthetic neuropeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences with an extensive published research base spanning neuroprotection, cognitive enhancement, BDNF upregulation, and clinical applications in ischemic stroke and optic nerve disease. This 30mg vial provides ≥99% purity material, HPLC and MS/MS verified per batch, suitable for high-throughput cell culture studies or multi-cohort animal research protocols.
Research Background
Semax’s primary mechanism of BDNF upregulation — documented at 140–200% increases in hippocampal BDNF in rodent studies — makes it a widely used tool for studying neurotrophin-mediated neuroprotection and synaptic plasticity. Published Russian clinical studies document its effectiveness in ischemic stroke recovery (improved neurological scores) and optic nerve atrophy (improved visual acuity and field parameters). The 30mg bulk vial is designed for researchers conducting larger scale studies or requiring significant quantities for extended protocol durations.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 30mg per vial
- Storage: −20°C, protected from light
- Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
- Molecular Weight: 813.9 Da
Certificate of Analysis
All Semax vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
